Preferred Label : Autologous Anti-B7-H3/CD19 CAR T-cells SCRI-CARB7H3(s)x19;
NCIt definition : A preparation of autologous CD4 and CD8 T-lymphocytes lentivirally transduced to
express a chimeric antigen receptor (CAR) targeting the immunoregulatory protein B7-homologue
3 (B7-H3, CD276) and the tumor-associated antigen (TAA) CD19, and containing, as of
yet undisclosed co-stimulatory signaling domains, and a truncated form of the human
epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic
activities. Upon administration, anti-B7-H3/CD19 CAR T-cells target and bind to both
B7-H3 on T-cells and CD19 on tumor cells. This crosslinks T-cells and tumor cells,
and induces selective toxicity in B7-H3/CD19-expressing tumor cells. B7-H3, a type
I transmembrane protein and a member of the B7 co-stimulatory protein superfamily,
is overexpressed on certain tumor cell types and on various immune cells. It promotes
the activation of T cells. CD19, a transmembrane phosphoglycoprotein expressed on
the surface of cells in the B lineage, are often overexpressed on malignant B-cells.
Devoid of both ligand binding domains and tyrosine kinase activity, the expressed
EGFRt both facilitates in vivo detection of the administered, transduced T-cells and
can promote elimination of those cells through a cetuximab-induced antibody dependent
cellular cytotoxicity (ADCC) response.;
Molecule name : SCRI-CARB7H3(s)x19;
NCI Metathesaurus CUI : CL1405603;
Origin ID : C171318;
UMLS CUI : C5417851;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
